TITLE

ALPHA METHYL DOPA IN HYPERTENSION

AUTHOR(S)
Datey, K. K.; Pandya, V. N.
PUB. DATE
April 1965
SOURCE
Angiology;Apr1965, Vol. 16 Issue 4, p155
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
1. Alpha methyl dopa was tried on 39 hypertensive patients. 2. Methyldopa is a decarboxylase inhibitor. However, its exact mode of hypertensive action is not clear. 3. It acts in about 3 to 4 hr., and the duration of its action is about 6 to 8 hr. The maximal effect occurs 24 to 48 hr. after instituting therapy. 4. When hypertension is mild to moderate in degree, the pressure is lowered mainly in the supine position, without much postural hypotension. 5. When hypertension is severe, the pressure is usually lowered in the upright position. However, in about one-third of the cases there is a significant fall in the sitting posture which is a distinct advantage. 6. The effect of exercise in the patients on treatment is discussed. 7. The side effects are not troublesome. An unusual one, constipation, occurred in this series. 8. Tolerance is sometimes rapidly established. 9. Though far from ideal, methyldopa is a welcome addition to the existing antihypertensive drugs. It has a few side effects ad is particularly useful in moderate hypertension.
ACCESSION #
16351057

 

Related Articles

  • A LONG-TERM STUDY OF COMBINED GUANETHIDINE AND HYDROCHLOROTHIAZIDE THERAPY IN THE MANAGEMENT OF HYPERTENSION. Kert, Morley J.; Dashe, Alfred M.; Mailman, Richard H.; Roth, Samuel I.; Zager, Albert // Angiology;Nov1962, Vol. 13 Issue 11, p511 

    1. Fifty-five outpatients were treated with guanethidine alone or in combination with hydrochlorothiazide in a long-term controlled study. 2. A clinically significant antihypertensive effect was demonstrated. This response was potentiated by hydrochlorothiazide. 3. The side effects were common...

  • Drugs yield "surprising" BP control.  // Cortlandt Forum;7/25/2005, Vol. 18 Issue 7, p18 

    Reports that a combination of irbesartan and hydrochlorothiazide can reduce systolic blood pressure (SBP) in patients with mild-to-moderate hypertension. Percentage on the reduction in SBP after eighteen weeks of combined therapy; Dosage of the combined therapy administered to the patients;...

  • Secondary stroke prophylaxis: ARB bests calcium antagonist.  // Formulary;May2005, Vol. 40 Issue 5, p157 

    Discusses a study which suggested that the angiotensin receptor blocker (ARB) eprosartan is superior to the calcium antagonist nitrendipine in secondary stroke prophylaxis in patients with hypertension. Findings reported by Dr. Hans-Chrisdan Diener at the American Stroke Association's...

  • HYPERTENSION.  // Current Medical Literature: Cardiology;2005, Vol. 24 Issue 4, p84 

    The article presents the comments of clinicians on several studies about hypertension. These include "Major clinical trials of hypertension: What should be done next?" "Resistant hypertension," "Superiority of ambulatory over clinical blood pressure measurement in predicting mortality: the Dubin...

  • Managing hypertension: a question of STRATHE. Zannad, F. // Journal of Human Hypertension;Jun2005 Supplement, Vol. 19, pS3 

    Current international guidelines recommend the use of therapeutic strategies with proven efficacy in the management of hypertension to achieve a target blood pressure of <140/90 mmHg. After lifestyle intervention, they endorse three different management strategies: (i) first-line use of a...

  • No Metabolic Side Effects of Long--Term Treatment with Verapamil in Hypertension. Midtbø, Kjell; Lauve, Oddveig; Hals, Ottar // Angiology;Dec1988, Vol. 39 Issue 12, p1025 

    In a prospective, open study 45 patients (mean age fifty-three years) with essential hypertension were treated with verapamil for four to eight years (mean 5.3 years). Blood pressure was satisfactorily controlled (from 160/104 to 145/91) and the side effects were infrequent, mild, and often...

  • Ouabain Antagonists as Antihypertensive Agents. Ferrandi, M.; Barassi, P.; Molinari, I.; Torielli, L.; Tripodi, G.; Minotti, E.; Bianchi, G.; Ferrari, P. // Current Pharmaceutical Design;Sep2005, Vol. 11 Issue 25, p3301 

    The evidence that high levels of endogenous ouabain (EO), a closely related isomer of ouabain, are implicated in human hypertension and cardiac hypertrophy and failure stimulated the pharmacological research for developing novel anti-hypertensive agents active as ouabain antagonists. The...

  • Azilsartan alone and in combination for the treatment of hypertension -- clinical utility and patient considerations. Jones, Jocelyn D.; Jackson, Sylvia H.; Colquitt, Charlie // Research Reports in Clinical Cardiology; 

    Hypertension is a common disease that leads to significant cardiovascular morbidity and mortality. Adequate blood pressure control is essential in preventing end organ complications. One of the most popular antihypertensive strategies for the treatment of elevated blood pressure is to attenuate...

  • High Blood Pressure, the Heart--and Hope: Are Prevention and Cure Being Ignored Because of a Fascination with Control Drugs? Renaurd, William // Nutrition Health Review: The Consumer's Medical Journal;2006, Issue 96, p12 

    The article presents a reprint of the article "High Blood Pressure, the Heart-and Hope: Are Prevention and Cure Being Ignored Because of a Fascination With Control Drugs," which appeared in issue 16 of the periodical "Nutrition Health Review." According to the article, the most valuable defense...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics